A complete guide for patients with advanced Peripheral Artery Disease and Chronic Limb-Threatening Ischemia — and what current research offers when standard treatments have stopped working
Written in the educational voice of Dr. York N. Hsiang, MB ChB, MHSc, FRCSC — Professor Emeritus of Surgery, UBC | Principal Investigator, Phase II ACP-01 Trial
You have already done the hard work. You showed up to every appointment, followed through with the procedures, and trusted the process — and yet, here you are.
A wound on your foot that will not heal. Pain in your leg that wakes you in the night. A surgeon you respect telling you, as gently as they can, that bypass surgery is no longer technically possible. That stenting cannot help. That the options have run out.
Perhaps the word amputation has been mentioned.
If that is where you are, this article was written for you — and for the family member or caregiver reading alongside you.
What follows is not a promotional pitch. It is a plain-language medical education resource based on current vascular science and peer-reviewed clinical research. My goal is to help you understand exactly what is happening in your leg, why conventional surgery sometimes cannot help, and what legitimate investigational research is now offering to patients in your situation.
You deserve honest information. Let’s start there.
|
In this article, you will learn: → What Peripheral Artery Disease (PAD) actually is and how it progresses → What Chronic Limb-Threatening Ischemia (CLTI) means and why it is serious → Why bypass surgery and stents sometimes stop being an option → What “no-option” CLTI means — and how common it really is → How angiogenesis works and why researchers are targeting it → What the Phase II clinical trial data on ACP-01 showed → Questions to ask before making any treatment decision |
Peripheral Artery Disease, or PAD, is a condition where the arteries carrying blood to your legs become progressively narrowed or blocked. The underlying cause, in the vast majority of cases, is atherosclerosis — the gradual buildup of plaque made up of fat, calcium, and inflammatory tissue along the arterial wall.
Over time, this plaque narrows the artery from the inside. Less blood gets through. Less oxygen and nutrients reach the tissues of the leg and foot. Eventually, the gap between what the tissues need and what they receive becomes critical.
PAD is most common in people over 60 and is strongly associated with:
Many people have more than one of these risk factors — and the combination significantly accelerates how quickly the disease progresses.
PAD does not arrive all at once. It typically progresses through recognizable stages:
Stage 1 — Asymptomatic PAD
The arteries are narrowing, but the body compensates. No symptoms yet. Many people are unaware they have PAD at this stage. It is often found incidentally on a vascular ultrasound or ankle-brachial index test.
Stage 2 — Claudication
The legs begin to cramp or ache during walking, then recover with rest. This happens because the narrowed arteries can supply enough blood at rest, but cannot meet the increased demand of exercise. Most people with claudication can manage the condition medically and with supervised exercise.
Stage 3 — Chronic Limb-Threatening Ischemia (CLTI)
Blood flow is now so severely reduced that the tissues cannot meet even their basic needs — even at rest. This is the stage where patients develop the symptoms that bring them to seek urgent help: persistent leg and foot pain at night, wounds that refuse to heal, and in the most severe cases, tissue that begins to die.
|
Key term: Ischemia Ischemia means inadequate blood supply to a tissue. When ischemia is severe enough to threaten the survival of the limb, it is called Chronic Limb-Threatening Ischemia, or CLTI. This is the clinical designation for the most serious stage of PAD. |
CLTI is not just "bad circulation." It is a specific clinical condition with defined characteristics, and it carries a serious prognosis if not treated effectively. Understanding what CLTI looks and feels like is the first step toward getting the right care.
1. Ischemic Rest Pain
This is pain in the foot, toes, or lower leg that occurs at rest — not just with walking. It is most severe at night, when the legs are horizontal and gravity no longer helps push blood toward the feet. Many patients describe having to hang their legs off the side of the bed, or sleep in a chair, to get any relief.
The pain is typically described as a burning or aching sensation in the foot or toes. It is not muscle cramps. It is the pain of tissue that is not receiving enough oxygen.
2. Non-Healing Wounds
Wounds on the foot, heel, toes, or lower leg that do not improve after weeks of appropriate wound care are a hallmark of CLTI. These wounds — also called ischemic ulcers — fail to heal because the tissue around them lacks the blood supply needed to support the cellular activity of wound repair.
Standard wound care treatments — dressings, antibiotics, offloading — can slow progression, but they cannot substitute for adequate circulation. Without restored blood flow, these wounds tend to worsen rather than improve.
3. Tissue Necrosis or Gangrene
In the most advanced cases, tissue begins to die. This may present as blackening or darkening of a toe, part of the foot, or a larger area of the lower leg. This is a medical emergency and typically leads to urgent amputation if circulation cannot be restored.
|
If you have any of these symptoms — rest pain, a non-healing wound, or tissue changes on your foot — and you have not yet seen a vascular surgeon, please seek evaluation urgently. Early evaluation significantly improves the range of options available to you. |
CLTI is not a rare condition, and its consequences are serious. The clinical data consistently show:
These are sobering numbers. But they also explain why researchers and clinicians are working urgently to find better solutions — particularly for the patients for whom conventional surgery is no longer possible.
When a patient is diagnosed with CLTI, the first goal is always to restore blood flow — a process called revascularization. Vascular surgeons approach this in two main ways:
When these procedures are successful, the results can be dramatic. Wounds heal. Pain resolves. Limbs are saved. For many patients, revascularization is an effective and durable solution.
But not for everyone. And not forever.
The feasibility of revascularization depends entirely on anatomy — specifically, which arteries are blocked and what remains of the vessels below the blockage.
Bypass surgery requires two things: a usable conduit (typically a vein harvested from the patient’s own leg), and a target vessel below the blockage — a relatively healthy artery to connect the bypass to. In patients with disease limited to large vessels like the aorta or femoral arteries, these targets are usually available.
But in patients with disease that extends into the smaller calf and foot arteries — the tibial and peroneal vessels — there may be no suitable target remaining. There is nowhere for the bypass to attach. The plumbing has been compromised all the way to the end.
Many patients who are now facing “no-option” CLTI have already undergone revascularization procedures in the past. Over time, these interventions may have:
When multiple experienced vascular surgeons conclude that further reconstruction is not feasible, that is what the term “no-option CLTI” formally means. It is a recognized clinical designation. It is not a failure of the surgeon, and it is not a judgment about the patient. It is an anatomical reality — and it is more common than many patients realize.
|
What does “no-option” CLTI mean? A patient has “no-option” CLTI when standard revascularization — bypass, angioplasty, or stenting — is not technically feasible, has already been attempted without durable success, or carries unacceptably high risk given their overall medical condition. It is a recognized clinical classification, not a final verdict on what is possible. |
To understand why researchers are now studying biological therapies, it helps to understand what is actually happening at the tissue level in advanced CLTI. Because the problem — and the solution — is not only about large arteries.
When a surgeon looks at your angiogram — the imaging test that maps blood flow in the arteries — they are seeing the large and medium-sized vessels: the aorta, the femoral artery, the tibial arteries. These are the highways.
But the actual delivery of oxygen and nutrients to your tissues happens through a completely different system: the microcirculation — a dense, microscopic network of tiny capillaries and arterioles that threads through every muscle, every layer of skin, every healing wound.
In patients with long-standing diabetes and advanced PAD, the microcirculation itself is often severely damaged. The tiny vessels have thickened walls, reduced flexibility, and impaired function. This means that even when a large artery is successfully opened by surgery, the tissue downstream may no longer have the capillary infrastructure to benefit from the restored flow.
This is one of the central reasons why reopening a blocked artery does not always save the limb.
It is tempting to think of a non-healing wound as simply a wound that lacks enough blood. The reality is more complex.
When tissue is starved of oxygen — a state called ischemia — a cascade of biological events is triggered:
A non-healing wound, in this sense, is not a wound waiting for blood flow. It is a wound caught in a biological stalemate. Breaking that stalemate requires something different from mechanical pipe-clearing. It requires biological repair — rebuilding the microvasculature from within.
The recognition that a significant population of CLTI patients cannot benefit from conventional surgery has driven decades of serious scientific investment in an alternative: biological therapies that stimulate the body’s own repair mechanisms.
The foundational insight is this: the body already knows how to grow new blood vessels.
Angiogenesis is the process by which new capillaries and blood vessels form from existing ones. It is not a theoretical concept — it happens naturally in your body every time a wound heals or a tissue recovers from injury. Under normal circumstances, cells in an oxygen-deprived area release chemical signals — growth factors — that stimulate nearby blood vessels to sprout and grow new branches toward the ischemic tissue.
In younger, healthier patients, this process is relatively efficient. In patients with advanced PAD, diabetes, and the vascular damage that comes with decades of disease, the angiogenic response is significantly impaired. The body’s repair signal is weak. Fewer stem and progenitor cells are mobilized. The ischemic tissue is less responsive.
The question driving the research is: can this process be restored or amplified therapeutically?
Early attempts to stimulate angiogenesis used gene therapy — delivering specific growth factor genes directly to ischemic tissue. The biology was promising, but clinical results were inconsistent. Delivering a single growth signal in isolation does not replicate the complex, co-ordinated biological process that normally occurs.
Attention then turned to cell-based therapies — approaches that use living cells to deliver the full, physiologically regulated mixture of growth signals that the body itself would produce in a functioning angiogenic response. The cells involved are called angiogenic progenitor cells — a population of specialized cells normally found circulating in the bloodstream that home to areas of low oxygen and participate in new vessel formation.
In patients with advanced PAD, these cells are present in reduced numbers and reduced function. The idea behind therapeutic delivery is to concentrate and deliver a meaningful quantity of these cells directly to the ischemic tissue — giving the body’s own repair system the resources it needs to do its job.
ACP-01 is an investigational autologous angiogenic cell therapy developed by Hemostemix. The term “autologous” is fundamental to understanding why this approach is distinct: the cells used in ACP-01 are derived exclusively from the patient’s own peripheral blood.
There is no donor involved. There is no risk of immune rejection. The therapy works with what your own body produces.
The process is designed to replicate and amplify what the body would naturally attempt — but cannot adequately achieve on its own in a patient with advanced PAD.
A Phase II randomized controlled trial of ACP-01 was conducted at Vancouver General Hospital, one of Canada’s leading academic vascular centres. The trial enrolled patients with Rutherford Class 5 and 6 disease — the most severe categories of limb-threatening ischemia, representing patients with active tissue loss and gangrene.
A sub-analysis of the trial examined outcomes specifically in the cohort of patients who had baseline ulceration — active non-healing wounds at the time of enrollment. These are among the most medically complex and high-risk CLTI patients.
|
4.8% Major amputation rate in ACP-01 group at 12 months |
25% Major amputation rate in placebo group at 12 months |
83% Overall limb salvage observed in no-option patients |
The data also showed that mortality at 12 months was 4.8% in the treated group compared with 12.5% in the placebo group.
|
How to interpret these numbers: These results come from a sub-analysis of a Phase II randomized controlled trial. A sub-analysis is an exploratory analysis of a specific patient subgroup within a larger trial. Phase II trials are designed to assess safety and early evidence of efficacy — they are not the same as large-scale Phase III trials or the evidence required for regulatory approval. What these findings do represent is a meaningful, peer-reviewed scientific signal. For patients who have no conventional options remaining, understanding what this early-stage research shows is genuinely important. |
Because ACP-01 remains investigational, patient access is currently limited to specific regulated pathways. These include:
In all cases, patients undergo a formal evaluation process — reviewing their imaging, medical history, and prior treatment — before any determination is made about suitability.
If you have reached the point where conventional revascularization is no longer possible, evaluating what comes next is one of the most important decisions you will face. Here is a framework for thinking about it clearly.
Before accepting that revascularization cannot help you, it is worth confirming that conclusion with more than one opinion. Vascular surgery is a technically demanding specialty, and expertise varies significantly between institutions. There are cases where a surgeon experienced in complex distal bypass or tibial-level reconstruction can identify an option that was not apparent elsewhere.
Consider seeking evaluation at:
That said, when multiple experienced surgeons at credible institutions have reached the same conclusion, it is reasonable to accept that conclusion and explore what research pathways may be available.
When evaluating any investigational option, ask these questions of the clinical team:
Your primary care physician, your current vascular surgeon, and your wound care team all have valuable context about your specific situation. A legitimate investigational program will welcome communication with your existing care team — not discourage it.
If a program asks you to avoid sharing information with your doctor, that is a red flag.
Being told that standard treatments have been exhausted is one of the hardest things a patient can hear. The combination of fear, uncertainty, and physical pain that accompanies advanced CLTI is real, and I do not want to minimize it.
What I want to offer instead is this: accurate information, placed in your hands, at the moment you need it most.
There is real, peer-reviewed scientific evidence that biological approaches to limb ischemia may offer meaningful benefit to patients for whom no mechanical option remains. That evidence is early-stage — honest science always is, at some point in its development — but it is genuine, it has been published and scrutinized, and it is advancing.
The fact that you are reading this, researching, asking questions — that matters. The right next step is an honest conversation with a clinical team who can review your specific situation and tell you plainly whether you might be a candidate for ongoing research, and what that would actually involve.
You deserve clarity. You deserve time to ask questions without pressure. And you deserve to make whatever decision is ahead of you from a place of knowledge, not fear.
|
Learn More — No Obligation, No Pressure The Hemostemix clinical patient team works with patients and their physicians to review medical history, prior imaging, and treatment records — and to determine individually whether a patient may be appropriate for evaluation in the ACP-01 research program. There is no obligation and no commitment involved in an initial conversation. We will tell you exactly what the research shows, what evaluation involves, and whether we believe we may be able to help. If we cannot, we will tell you that too. To speak with a member of our clinical team or request a consultation, visit hemostemix.com or contact us directly. Access pathways are available in Florida, Toronto, and internationally. |
|
Medical & Regulatory Disclaimer ACP-01 is an investigational therapy and has not been approved by Health Canada, the U.S. Food and Drug Administration (FDA), or any other regulatory authority for the treatment of Peripheral Artery Disease, Chronic Limb-Threatening Ischemia, or any other condition. Clinical data referenced in this article is preliminary and exploratory in nature. This article is intended for educational purposes only. It does not constitute medical advice and should not be used as the basis for any clinical decision without consultation with a qualified physician. Individual outcomes cannot be predicted or guaranteed. |
These are the questions patients most often bring to their first conversation with our clinical team.
“No-option” CLTI is a recognized clinical designation for patients in whom standard revascularization procedures — bypass surgery, angioplasty, stenting — are not technically feasible, have already been attempted without lasting success, or carry unacceptably high procedural risk. It does not mean that nothing can be done about your condition. It specifically means that conventional mechanical restoration of blood flow through surgery is not available. Investigational biological therapies are being studied specifically for this patient population.
Prior failed revascularization does not disqualify you from consideration for investigational therapy. The Phase II trial of ACP-01 specifically enrolled patients who were defined as having no conventional options remaining — including patients with prior failed bypass and stenting. Whether you are individually appropriate requires a review of your specific imaging and medical history. The best first step is to request an evaluation consultation.
Any wound on the foot or lower leg in a patient with known PAD or diabetes that has not shown clear improvement after four to six weeks of appropriate wound care warrants urgent vascular evaluation. In CLTI patients, a non-healing wound is not simply a wound care problem — it is a sign of critically reduced perfusion. Delays in addressing the underlying vascular cause are consistently associated with worse outcomes, including higher rates of major amputation. Do not wait for the wound to become an emergency.
Yes, without hesitation, and I would say this even as a vascular surgeon myself. A second — and sometimes third — opinion from an experienced vascular surgeon at a high-volume academic centre is entirely appropriate before proceeding with major amputation. There are cases where limb salvage options not initially identified become apparent with additional expertise or imaging. Even when the conclusion is the same, having multiple experienced clinicians agree provides important context for your decision-making. After exhausting conventional options, it is also appropriate to ask about investigational research programs.
Angiogenesis is the biological process by which new blood vessels form and grow. It is your body’s natural response to areas of poor blood supply: cells in oxygen-deprived tissue release chemical signals that stimulate nearby vessels to sprout new branches. In patients with advanced PAD, this repair response is impaired — fewer angiogenic cells are mobilized, and the ischemic tissue responds less effectively. Investigational cell therapies like ACP-01 are designed to amplify this process by delivering a concentrated dose of the patient’s own angiogenic cells directly to the affected tissue, with the goal of stimulating new capillary formation and improving microvascular perfusion.
No. ACP-01 is an investigational therapy. It is not approved by Health Canada, the FDA, or any other regulatory authority for general clinical use. It is available through specific regulated access pathways — in Florida under Senate Bill 1768, in Toronto through compassionate access, and internationally in the Bahamas and Dominican Republic. All patients undergo individual evaluation before any treatment discussion. The published Phase II clinical data is encouraging, but it is early-stage evidence, not the standard required for regulatory approval.
In most cases, standard health insurance plans do not cover therapies that have not received regulatory approval. Coverage varies by jurisdiction, insurer, and individual policy — and it is worth contacting your insurer directly to ask specifically about investigational therapy coverage. Patients who choose to pursue investigational options through regulated access programs typically do so on a private basis after exhausting covered treatments. The Hemostemix clinical team provides transparent, upfront information about all associated costs during the evaluation process. There is no cost for the initial consultation.
About This Article
This educational resource reflects the scientific perspective of Dr. York N. Hsiang, MB ChB, MHSc, FRCSC — Professor Emeritus of Surgery, University of British Columbia, and former Head of Vascular Surgery at Vancouver General Hospital. Dr. Hsiang is the Principal Investigator for the Phase II clinical trial of ACP-01 in no-option Critical Limb-Threatening Ischemia.
Clinical data referenced: Henderson et al. (2024), Phase II sub-analysis, Vancouver General Hospital. For full citations and scientific publications, visit hemostemix.com/scientific-publications.